ConductScience.org, home

Paper37815596

Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer.

Yadav A and 2 others. Med Oncol, 2023. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer. Papers, record 37815596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37815596

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer.
PubMed
Journal
Med Oncol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.43
iCite
Revised in PubMed
2026-10-31
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yadav AAgrima
2Yadav SShikhahttps://orcid.org/0000-0002-2816-8273
3Alam MAMd Aftab

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Uterine Cervical NeoplasmsMajor topic
Humans
Female
Immunotherapy
Combined Modality Therapy
Human Papillomavirus Viruses

References103

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127171673Advances in diagnosis and treatment of metastatic cervical cancer.J Gynecol Oncol2016https://conductscience.org/library/papers/27171673PubMed
217704786Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.Nat Med2007https://conductscience.org/library/papers/17704786PubMed
320411564Modulating numbers and phenotype of CD8+ T cells in secondary immune responses.Eur J Immunol2010https://conductscience.org/library/papers/20411564PubMed
430943124Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol2019https://conductscience.org/library/papers/30943124PubMed
529095678Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.J Clin Oncol2017https://conductscience.org/library/papers/29095678PubMed
629538258A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer.Int J Gynecol Cancer2018https://conductscience.org/library/papers/29538258PubMed
731428574Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System.Front Oncol2019https://conductscience.org/library/papers/31428574PubMed
87622099New gynecologic cancer staging.Gynecol Oncol1995https://conductscience.org/library/papers/7622099PubMed
918980286HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.Cancer2008https://conductscience.org/library/papers/18980286PubMed
1010202165Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med1999https://conductscience.org/library/papers/10202165PubMed
1114985791Comparison of HPV DNA vaccines employing intracellular targeting strategies.Gene Ther2004https://conductscience.org/library/papers/14985791PubMed
1210822298Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.Gene Ther2000https://conductscience.org/library/papers/10822298PubMed
1317341658CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women.Carcinogenesis2007https://conductscience.org/library/papers/17341658PubMed
1425752814Human papillomavirus molecular biology and disease association.Rev Med Virol2015https://conductscience.org/library/papers/25752814PubMed
1523615841Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.Cancer Immunol Immunother2013https://conductscience.org/library/papers/23615841PubMed
1618483387Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.Clin Cancer Res2008https://conductscience.org/library/papers/18483387PubMed
1726901118Current state in the development of candidate therapeutic HPV vaccines.Expert Rev Vaccines2016https://conductscience.org/library/papers/26901118PubMed
1820170766Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7.Vaccine2010https://conductscience.org/library/papers/20170766PubMed
1919890126Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.N Engl J Med2009https://conductscience.org/library/papers/19890126PubMed
20762493Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro.J Exp Med1979https://conductscience.org/library/papers/762493PubMed

See all 103 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
41234865CC/CXC chemokine risk signature at single-cell resolution: a machine learning model for precision stratification in cervical cancer.Transl Cancer Res2025https://conductscience.org/library/papers/41234865PubMed
40227870Role of Fascin-1 in cervical cancer metastasis via Wnt/β-catenin pathway activation.Biomol Biomed2025https://conductscience.org/library/papers/40227870PubMed
40124621TGF-β-mediated activation of fibroblasts in cervical cancer: implications for tumor microenvironment and prognosis.PeerJ2025https://conductscience.org/library/papers/40124621PubMed
38840928Immune cell infiltration and prognostic index in cervical cancer: insights from metabolism-related differential genes.Front Immunol2024https://conductscience.org/library/papers/38840928PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GZMH2999PubTator's text mininghttps://conductscience.org/library/genes/2999NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37815596

GET https://conductscience.org/api/papers/v1/37815596/references?page=2